Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
NetherlandsIPO:
18 May 2017Website:
http://www.argenx.comNext earnings report:
25 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:41:21 GMTDividend
Analysts recommendations
Institutional Ownership
ARGX Latest News
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development
On May 2, 2024, argenx, a worldwide immunology company dedicated to enhancing the quality of life for individuals with severe autoimmune conditions, revealed that it will be holding a conference call and audio webcast on Thursday, May 9, 2024 at 2:30 PM CET (8:30 AM ET) to review its financial performance for the first quarter of 2024 and give an update on its operations.
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
argenx SE (ARGX) Q4 2023 Earnings Call Transcript
What type of business is argenx SE?
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
What sector is argenx SE in?
argenx SE is in the Healthcare sector
What industry is argenx SE in?
argenx SE is in the Biotechnology industry
What country is argenx SE from?
argenx SE is headquartered in Netherlands
When did argenx SE go public?
argenx SE initial public offering (IPO) was on 18 May 2017
What is argenx SE website?
https://www.argenx.com
Is argenx SE in the S&P 500?
No, argenx SE is not included in the S&P 500 index
Is argenx SE in the NASDAQ 100?
No, argenx SE is not included in the NASDAQ 100 index
Is argenx SE in the Dow Jones?
No, argenx SE is not included in the Dow Jones index
When does argenx SE report earnings?
The next expected earnings date for argenx SE is 25 July 2024